Your session is about to expire
← Back to Search
Rituximab + Hyaluronidase with Immunotherapy for Melanoma
Study Summary
This trial looks at whether a two-drug combo can prevent harmful immune reactions in people with advanced melanoma who are also receiving other immunotherapy treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver function tests are within the required range.I am not on steroids for an autoimmune disease.Your LDH blood test result is not more than 10 times the upper limit of normal.My cancer has spread to my brain or spinal cord.I had ipilimumab, nivolumab, or pembrolizumab over a year ago without severe side effects.I have had treatments like immune therapies or vaccines before.I have been treated with interferon in the past.I do not have active hepatitis B or C.I am allergic to rituximab or its components.Your total bilirubin levels should be within a certain range, unless you have a specific condition called Gilbert's syndrome.Your hemoglobin level is at least 9 grams per deciliter.I do not have and have never had inflammatory bowel disease.You have a white blood count of at least 3,000 per microliter.Your alkaline phosphatase level is not too high, unless you have bone metastasis.I am eligible for standard melanoma treatment with ipilimumab and nivolumab.I am not on corticosteroid therapy, except for replacement needs.I haven't had immune checkpoint inhibitor therapy in the last year.I do not have autoimmune disorders like lupus or type I diabetes.Your white blood cell count is at least 1,500 per microliter.Your platelet count is at least 100,000 per microliter.My kidney function, measured by creatinine levels, is within the normal range.
- Group 1: Arm A (standard of care)
- Group 2: Arm B (rituximab, hyaluronidase human)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What maladies has Rituximab and Hyaluronidase Human been shown to ameliorate?
"Rituximab and Hyaluronidase Human can be used as treatments for b-cell lymphomas, polyangium, and malignant neoplasms."
Are people with the qualifying condition able to participate in this research project at this time?
"This trial, which was originally posted on June 5th, 2019 and last updated on June 27th, 2022, is currently looking for participants."
Are Rituximab and Hyaluronidase Human commonly used in other medical studies?
"Currently, 1232 clinical trials are ongoing which investigate Rituximab and Hyaluronidase Human. Of these studies, 188 are in Phase 3. Wuhan is running out of locations for these types of study however Other has 59793 active sites."
How many people are the most that can be a part of this research project?
"That is correct, the online information about this clinical trial reveals that it is still recruiting patients. The study was first posted on June 5th, 2019 and has been updated as recently as June 27th, 2022. The aim is to recruit 44 patients from a single location."
What are the short-term risks associated with taking Rituximab and Hyaluronidase Human?
"There is early clinical data suggesting that Rituximab and Hyaluronidase Human are safe, but no studies have been done to confirm efficacy. Therefore, it received a score of 2."
Share this study with friends
Copy Link
Messenger